唑来膦酸注射液用于骨质疏松时急性期反应的危险因素及处置措施

Risk factors and measures of acute-phase reactions caused by zoledronic acid injection for treating osteoporosis

与口服制剂相比,唑来膦酸注射液治疗骨质疏松时每年输注1次,可有效提高患者的用药依从性。但是临床输注唑来膦酸时,发热、头痛、肌痛、关节痛等急性期反应的发生率非常高。急性期反应(APR)的发生率可能与年龄、种族、体重指数、骨吸收抑制药的应用、血25(OH)D水平相关。非甾体抗炎药可用于急性期反应的防治。本研究旨在对注射唑来膦酸后发生急性期反应的危险因素及处置措施进行总结,旨在为临床提供参考。

Zoledronic acid injection used for treating osteoporosis is infused once a year. However,clinical practice suggested that the incidence of acute-phase actions（ APRs）,such as fever,headache,myalgia and arthralgia were very high. The incidence of APRs reported was associated with age,species,body mass index,the use of bone resorption inhibitors,and serum 25（ OH） D. Non-steroidal anti-inflammatory drugs could be used to prevent and treat the symptoms of APRs. The review aims to summarize the risk factors and measures of APRs caused by zoledronic acid injection.